Benjamin Miron, MD, shares his expertise on treatment selection in the first-line setting for patients with urothelial carcinoma.
Miron, a second-year hematology/oncology fellow at Fox Chase Cancer Center, presented a real-world study at the 2021 ASCO Annual Meeting that explored the influence of first-line chemotherapy choice on overall survival outcomes in patients with advanced urothelial carcinoma who received immunotherapy in the second-line setting.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.